Disease and death caused by bacterial infections is a global health problem. Effective bacterial strategies are required to promote survival and proliferation within a human host and it is important to explore how this adaption occurs. However, the detection and quantification of bacterial virulence factors in complex biological samples are technically demanding challenges. These can be addressed by combining targeted affinity enrichment of antibodies with the sensitivity of LC-SRM MS. However, many virulence factors have evolved properties that make specific detection by conventional antibodies difficult. We here present an antibody format that is particularly well suited for detection and analysis of IgG-binding virulence factors. As proof of concept we have generated scFv antibodies that specifically targets the IgG-binding surface proteins M1 and H of Streptococcus pyogenes. The binding ability of the developed scFv is demonstrated against both recombinant soluble protein M1 and H as well as the intact surface proteins on a wild-type S. pyogenes strain. Additionally, the capacity of the developed scFv antibodies to enrich their target proteins from both simple and complex backgrounds, thereby allowing for detection and quantification with LC-SRM MS, was demonstrated. We have established a workflow that allows for affinity enrichment of bacterial virulence factors.
INTRODUCTION
Bacterial infectious diseases are a major cause of death worldwide. The survival and proliferation of a bacterial pathogen inside the human host requires effective bacterial defense strategies to evade host innate and adaptive immune system. These evasion strategies are orchestrated by a large number of virulence factors expressed by the bacteria responsible for degrading or binding to specific host proteins to enhance bacterial survival. The complex and sometimes redundant function of the virulence factor repertoire requires quantitative measurement of both virulence factors and host proteins to reveal the molecular mechanisms behind virulence and antimicrobial resistance, which is an increasingly serious threat to global public health 1 . The rapid development of mass spectrometry based proteomics techniques has resulted in several studies outlining close to complete relative quantitative analysis of bacterial proteomes, showing how bacterial pathogens can adapt to host-like environments in vitro 2, 3 . Via the use of heavy labeled stable isotope reference peptides, absolute protein quantification of a substantial part of the bacterial proteome is possible 4,5 , 6 . However, to accurately determine how bacterial pathogens adapt to the host in vivo, absolute measurement of important virulence factors during the disease process directly in samples obtained from in vivo is required.
Selected reaction monitoring (SRM) mass spectrometry has increasingly been applied for more quantitatively accurate measurements of predetermined sets of proteins 7 . In SRM, a priori defined tryptic peptides generated from whole proteome digests are specifically and exclusively targeted with developed SRM assays using triple quadrupole mass spectrometers, providing identification and quantification of proteins with high sensitivity and specificity 7 . Yet, mass spectrometric measurements of specific bacterial proteins from in vivo isolated samples, such as swabs or body fluids like blood plasma, serum and cerebrospinal fluid, is challenging as abundant host proteins can prevent identification of the target proteins. A promising strategy to enable quantitative analysis of minute amounts of target proteins in complex biological samples is to combine the sensitive detection and quantification of SRM with targeted immunoaffinity enrichment using antibodies. Several different platforms combining the sensitivity of antibody enrichment with the specificity of mass spectrometry analysis have been established for quantitative measurements of proteins in plasma and serum [8] [9] [10] [11] . In addition, the use of antibodies has also become increasingly important for tracking specific microorganisms in various infectious diseases 12, 13 .
Developing specific antibodies for microorganisms can be challenging for several reasons. Firstly, the efficient capture of a specific protein from a microorganism requires that the targeted protein is available in the extracellular space. This means that the protein needs to be surface exposed or secreted and constitutively expressed under in vivo conditions, preferably at high concentrations. Secondly, the targeted epitope needs to be accessible. Many microorganisms have developed strategies to avoid detection by antibodies, by for example, binding to host proteins to mask the immunogenic parts of the bacterial proteins 14 , whereas other parts of the protein can be hypervariable 14 . For example, several pathogenic bacteria produce proteins that can immobilize immunoglobulin G (IgG) by binding the fragment crystable (Fc) part of IgG [15] [16] [17] [18] . The presence of IgGFc-binding proteins can protect the bacteria against phagocytosis and the bacteria is thereby protected in its natural environment 19 . These IgGFc binding surface proteins makes it difficult to specifically detect and capture the bacteria in a complex mixture using affinity probes such as antibodies. Lastly, the development of antibodies against bacterial proteins with methods relying on immunization can potentially be problematic due to the toxicity of these.
Immunoaffinity enrichment or immunological detection requires a suitable antibody or capture molecule. The availability of appropriate antibodies still remains a major bottleneck in the establishment of immunoassays 8 . Phage display-technology 20, 21 is the most commonly used in vitro system for the development of specific antibodies. In phage display the antibody is displayed on the surface of the phage particle while the genes encoding the antibody is kept within the phage particle 22 . By cloning millions of genes encoding different antibodies into the phage genome, large libraries can be created and used for isolation of antibodies with desired specificities and characteristics 22 .
Antibody phage display libraries are often constructed with either single chain variable (scFv) or Fab fragments 23 . The scFv antibody format consists of the variable regions of the antibody connected by a linker thereby retaining its antigen binding ability but having no Fc region. Consequently, the use of this format diminishes the risk of IgGFc-binding between the target protein and the antibody.
The major aim of this study was to develop antibodies suitable for immunoaffinity enrichment through phage-display technology to enable bacterial detection with SRM mass spectrometry in complex samples, using the major human pathogen Streptococcus pyogenes as a model system. One of the most abundant surface proteins expressed by S. pyogenes is the M protein, which is regarded as a major virulence factor due to its antiphagocytic ability 24 . The M protein is expressed on the bacterial surface, but local considerable concentrations of secreted M protein can be reached due to self-cleavage from the bacterial surface 25 . There are more than 100 different serotypes of the M proteins 26 , all consisting of a hypervariable N-terminal, a less variable central domain and a more well conserved C-terminal 27 . The M1 protein consists of repeat regions, starting with the 91 amino acid long A domain at the N-terminus, followed by two repeat sequences of 28 residues each (domain B1 and B2) and then a 35 amino acid, non-repeat sequence (domain S). Following the S domain is three repeat regions of respectively 42, 42 and 31 amino acids (domains C1, C2 and C3) and then the rest of the protein consists of the D domain 28 . The binding sites of plasma proteins albumin, fibrinogen and IgG are mapped to the C domains, B domains and S domain respectively 28 29 . Some S. pyogenes strains also produce M-like proteins such as protein H 28 30 32 . An in vitro system, such as phage display, that would allow us to by-pass immunization, is therefore particularly desirable when generating antibodies against these types of bacterial proteins.
In this article, we show the isolation of scFv fragments against protein H and M1 of S. pyogenes using phage display. A particular vector construct was used that allows for site-specific in vivo biotinylation whilst expressing the scFv 33, 34 . This format allows us to overcome the typical shortcomings of using full-length antibodies to analyze Fc binding antigens, which potentially could lead to a non-specific assay. We show that the developed scFv antibodies specifically bind their target proteins both as soluble proteins as well as a part of the intact bacteria. The developed scFvs were further shown to have the ability to enrich their target proteins and successfully enable detection in complex samples by SRM-MS. To conclude, a workflow has been established that allows immunoaffinity enrichment of bacterial target proteins.
EXPERIMENTAL PROCEDURES

Materials
Streptococcal proteins M1 and H were produced and purified as previously described 28, 32, 35 . The bacterial strains AP1, BM27.6, MC25 and BMJ71 were cultured as previously described 36, 37 . The M1 peptide fragments ABS, AB, DCS and DC were kindly provided by Prof. Lars Björk (Division of Infection Medicine, Lund University). Antibody fragments were selected against the target proteins from the Hell-11 phage display library. In short, HELL-11 is a human synthetic scFv library based on heavy chain (IGHV3-23) combined with either kappa light chain (IGKV1-39) or lambda light chain (IGLV1-47). Diversity was mainly restricted to surface-exposed residues in four of the six complementarity determining (CDR) loops; CDR-H1, CDR-H2, CDR-H3 and CDR-L3, using trinucleotide primers and an optimized Kunkel mutagenesis methodology similar to previously described by Fellouse and Sidhu 38 . Library size was estimated to >2 x 10 10 unique members, as measured by the number of bacterial colonies obtained after transformation.
Selection of specific scFv antibodies by phage display
Phage display selections were performed on proteins M1 and H, 1 ml of target proteins at a concentration of 5 μg/ml in phosphate buffered saline (PBS) was immobilized in immunotubes (Nunc A/S, Roskilde, Denmark) over night at 4 °C. Unbound protein was removed by washing once with 4 ml 0.05% Tween20 in PBS (PT) and subsequently blocked at room temperature for 1 hour with 0.5% BSA and 0.05% Tween20 in PBS (PBT).
In order to remove potential non-specific binders, the phage stock was prior the selection incubated with immunotubes coated over night at 4 °C with 2 ml streptavidin at a concentration of 5 mg/ml in PBS. Subsequently, the phage stock was transferred to the antigen-coated immunotube and incubated for 1.5-2 hours with slow rotation at room temperature. The immunotubes were washed 6-11 times with PT followed by one wash with PBS. Bound phages were eluted with 1 ml trypsin at a concentration of 0.5 mg/ml and incubated for 30 minutes at room temperature. The enzymatic activity of trypsin was inhibited by the addition of 0.5 ml aprotinin (0,2 mg/ml). The eluted phages were propagated by infection of E.coli XL1-blue (Stratagene, La Jolla, CA, USA), infected with M13K07 (New England Biolabs, Ipswich, MA, USA) for phage production and amplified in solution over night at 30 °C. Harvested phage stocks were precipitated with PEG8000/NaCl and re-suspended in PBT. The precipitated phage stock were used for subsequent selection rounds as described above with the exception that the protein target concentration was decreased to 2.5 μg/ml in the third round and to 1.0 μg/ml in the fourth round.
Re-cloning of specific scFv antibodies and determination of specific binding
DNA from the third and fourth round of selection was isolated and recloned to allow production of scFv antibodies in a soluble format. The DNA was digested with SfiI and Waltham, MA, USA). The purity of the purified scFvs was confirmed by SDS-PAGE and an ELISA assay, as described above, was performed to confirm the binding specificity.
Production and Purification of soluble antibody fragments
Bacteria ELISA
In order to evaluate the binding capacity of the generated scFv on whole bacteria, the soluble scFv clones were analyzed in an in-house developed bacteria ELISA. The bacterial strain (AP1, MC25 or BMJ71) was immobilized at a concentration of 10 6 cfu in 384-well plates (Corning Inc.) and incubated over night at 37 °C. After one washing step and blocking with PBT, the scFvs were added and the ELISA performed as describe above.
Epitope mapping ELISA
The binding profile for the two scFv antibodies developed against protein M1 were further investigated by including peptide fragments of the M1 protein. The peptide fragments and full-length M1 were immobilized at a concentration of 5 μg/ml and 1 μg/ml in 384-well plates (Corning Inc.), respectively, and incubated over night at 4 °C. After one washing step and blocking with PBT, the scFvs were added and the ELISA performed as describe above.
Selection of target peptides and transitions
SRM assay were constructed by testing at least the ten most abundant peptide fragments for selected proteotypic peptides. Proteins that were selected for detection in addition to protein M and H were the human proteins Apolipoprotein E, Immunoglobulin γ (1-4) and Fibrinogen (α, β, γ). The scFv antibodies as well as streptavidin, constituting the proteins on the bead surface, were also selected along with retention time normalization peptides. The streptococcal proteins M1 and H were measured and absolute quantified using heavy isotope labelled peptides (HeavyPeptide AQUA, Thermo Fisher Scientific Inc. and JPT, Berlin, Germany). Only top-performing peptides for each protein was selected (data not shown), one to three peptides were selected for final SRM analysis for each protein. The four to five transitions with highest intensity was selected for each peptide with the exception of the retention time peptides that have two transitions each. A full list of the SRM assay can be found in the supplement table S1.
Capture of target proteins in PBS or a serum background
Soluble biotin-tagged scFv (2.5 μg) were coupled to magnetic Dynabeads M-270 streptavidin (Invitrogen Dynal AS, Oslo, Norway) for 1 hour at room temperature with shake according to manufacturers instructions. 100 μg of coupled beads were used for each capture reaction. Recombinant target proteins were spiked in PBS or 10% human serum (Sigma-Aldrich Corp, St. Louis, MO USA) diluted in PBS at a concentration of 0, 20, 100 and 500 ng/ml. A magnetic bead processor, KingFisher Flex (Thermo Fisher Scientific Inc.), was used for the automated capture procedure. The procedure included two washes of the scFv-coupled beads in 1 ml 0,05% Tween20 in PBS, followed by 1-hour incubation with the target protein spiked samples. The beads were, after sample incubation, washed 3 times in 0.1% CHAPS in PBS, once in 0.03% CHAPS in PBS and once with 0.03% CHAPS in 50 mM ammonium bicarbonate and afterwards transferred to Eppendorf tubes (Maximum recovery tubes, Axygen). Subsequently, the wash solution was removed and 15 μl of 12 ng/ml trypsin (Sequencing grade modified, Promega Corp.) was added. The trypsin digestion was carried out for 5 h at 37 °C with shake, followed by addition of 1,5 μl of 5% formic acid. The samples were dried and reconstituted in 0.1% formic acid, 3% acetonitirle and transferred to HPLC vials for LC-SRM MS.
LC-SRM analysis
The SRM measurements were performed on a TSQ Vantage triple quadrupole mass spectrometer (Thermo Fisher Scientific Inc, San Jose, CA, USA) equipped with a nano electrospray ion source (New Objective, Woburn, MA, USA), mass spectrometric settings were previously described 19 . Chromatographic separations of peptides were preformed on an Easy-nLC II system (Thermo Fisher Scientific Inc.), the non-linear gradient ranging from 3-10% acetonitrile over 3 minutes and from 10-32% acetonitrile over 34 minutes with a flow-rate of 300nl/min. PicoChip (New Objective) columns packed with Reprosil-PUR C18, a length of 105 mm, inner diameter of 75 μm and a tip size of 15 μm were used.
Data Analysis
The data was analyzed in the SRM management software Skyline (MacCoss Lab Software, University of Washington). All data is published on a Panorama server, se supporting information.
RESULTS
Development of scFv antibodies
Streptococcus pyogenes express a wide range of surface associated and secreted virulence factors. Screening for highly abundant virulence factors using stable isotope labeled reference peptides and SRM revealed that proteins H and M1 are among the most abundant virulence factors present on the S. pyogenes AP1 strain surface (data not shown).
These two virulence factors were produced in recombinant full length form excluding the N-terminal signal sequence and the C-terminal cell-wall anchor region. Importantly, these recombinant formats have been proven active and biologically relevant mimics of their native counterparts 25, 28, 39, 40 . Phage display was then used to isolate scFvs, binding protein H and M1 using an in-house generated human synthetic scFv phage display library consisting of more than 1 x 10 10 unique clones. The antigen binding capacity of an scFv is kept intact by linking the antibody variable regions by a peptide linker while the Fc-region of the antibody is removed (Figure 1a ) thereby avoiding the binding between the developed antibody and the IgGFc binding domain of the target proteins. In addition, we used a production system that allows site-specific biotinylation using a biotin acceptor domain (BAD) and biotin ligase BirA for site-specific in vivo biotinylation of the developed scFvs (Figure 1b) . The biotinylated scFv format enables the use of streptavidin as secondary reagent rather than antibodies traditionally used in immunoassays, such as ELISA and FACS. Importantly, we observe no binding between protein M1, protein H or the S pyogenes wild-type strain, AP1, expressing both M1 protein and protein H, when using streptavidin as a secondary reagent in the ELISA analysis (data not shown). By making use of scFv in combination with streptavidin, the Fc region is omitted in both the primary and secondary interaction steps, ensuring that the observed binding is not 
scFv antibodies recognize protein H and the M protein on the surface of S pyogenes
The binding abilities of the scFvs were also investigated on whole S. pyogenes bacteria.
We used the wild-type AP1 (wt) strain expressing high levels of both the M1 protein and protein H and two isogenic mutants, MC25 and BMJ71. BMJ71 is an mga-negative strain (H-, M-), which do not express the proteins M1 and H 36 , whereas MC25 (H+, M-) has no cell wall anchored domain of the M1 protein and can only produce M1 protein in secreted form 37 . The binding of the scFvs to the bacterial strains was assessed in a developed bacteria ELISA (Figure 3 ). All the developed scFv antibodies were found to bind the intact native surface proteins M1 and H present on the bacterial surface of the wild-type strain ( Figure 3a) . As expected, none of scFv antibodies bound to the H-M-strain (Figure 3b ).
The scFv antibodies directed against protein H did bind to the H+, M-strain (Figure 3b 
Immunoaffinity enrichment of target proteins
The scFv antibodies were further investigated for their capacity to enrich the target proteins from PBS as well as a complex serum background to enable quantification using LC-SRM MS. The biotin-tag on the scFv antibodies was used to couple the scFv antibodies to magnetic streptavidin beads. The target proteins were spiked in PBS in a concentration range of 0-500 ng/ml and enriched using the antibody coupled magnetic streptavidin beads followed by on-bead trypsin digestion, separated using liquid chromatography (LC) and analyzed by LC-SRM. MS. Peptides selected for analysis is presented in table S1. By selecting the five most intense fragments for each peptide the set of transitions analyzed by LC-SRM MS is generated. Prior to LC-SRM MS heavy labeled aqua reference peptides were added for absolute protein quantification. The SRM data reveals a high linearity and the respective target protein was at least detectable in samples with an initial concentration down to 4 ng/ml (80 fmol/ml and 100 fmol/ml for M1 and H respectively) (Figure 4a & 4b) . Importantly, no target proteins are detected in samples with noncoupled magnetic beads or in samples spiked with 500 ng/ml of a non-target protein (Figure 6a ). This indicates that the enrichment is specific, mediated by the scFv antibodies, and that there is no cross-reactivity for the scFv antibodies against respective non-target protein.
The efficacy of the enrichment in PBS is expressed as the ratio between the theoretical maximum amount and the actual detected amount of the target protein, determined via the heavy labeled aqua reference peptides. A high efficacy was attained, especially for the low concentration samples, as can be seen in figure 4c and 4d. Although an efficacy close to 1.0 is desirable it is unlikely due to possible sample loss during the various sample processing steps. Still, the efficacy of the enrichment of M1 protein was above 0.5 for all samples analyzed and was relatively stable over the whole concentration range with the exception for the highest concentration sample (Figure 4c) . A lower efficacy can be seen for the enrichment of protein H compared to protein M1. There was also a larger decrease in efficacy for the higher concentrations of protein H (Figure 4d ).
The decrease in efficacy for both protein M1 and H capture at the highest target protein concentration (500 ng/ml) can potentially be explained by a limited amount of available scFv. There is also a possibility for crowding effects on the beads, meaning that even though scFvs are available on the beads, the high antigen concentration surrounding the beads and steric hindrance hinders the scFv from binding target protein. (Figure 6b ). In these experiments, M1 protein was below detection limit, indicating that the enrichment is dependent on specific enrichment mediated by the scFv antibodies.
DISCUSSION
In this work we have used phage display to develop scFv antibodies against the S. pyogenes surface proteins M1 and H. The generated scFv antibodies showed sensitive and specific binding against their respective target proteins. Importantly, the antibodies were demonstrated to bind both the soluble, recombinantly produced target proteins as well as the intact native surface protein M1 and H on the bacterial surface of wild-type strain AP1. In addition, we showed that the antibodies had the ability to enrich its target antigens from both PBS and a complex serum background to enable detection and quantification with LC-SRM MS.
Many bacterial pathogens express surface proteins capable of binding IgGFc to avoid detection of the host immune system, an ability that both target proteins, M1 and H, used in this study have 18, 28, 30 . The IgGFc binding ability complicates the specific detection of the target proteins, mediated by the antigen binding site, due to potential binding via the Fc region both from the developed antibodies as well as from secondary detection antibodies used in different immunoassays. To address these challenges we used a specific format of the developed antibodies associated with several key advantages.
Firstly, the scFvs have no Fc-part, as illustrated in Figure 1 . Secondly, we make use of sitespecific biotinylation, which allows us to use streptavidin as a secondary agent. Several detection assays such as ELISA and FACS rely on secondary antibodies. Combining the scFv format with biotin omits the Fc region from both the primary and secondary interaction steps, ensuring that the observed binding is not contributed by the Fc domain.
Proteins can be chemically labeled with biotin through incorporation of biotin at primary amines (e.g. side chains of lysine) 41 . However, the uncontrollable inclusion of biotin with chemical labeling is unspecific and the incorporation at certain positions can affect the proteins activity as well as their conformations 41, 42 . Therefore, the use of site-specific labeling is favorable. Different approaches have been taken to imitate the biotinylation process performed in nature by taking advantage of enzymatic biotinylation sites 33, 34, 43, 44 to control the site where the biotin is attached. Here we have used the biotin ligase enzyme BirA from E. coli and a 16 amino acid long biotin acceptor domain (BAD) for in vivo site-specific biotinylation of the selected scFvs (Figure 1b) to contain proteins spanning a high dynamic range. Serum contains proteins ranging over 9 orders of magnitude in concentration 45 and without sample fractionation, low abundant proteins will not be detected due to the complex background. SRM has an exceptional sensitivity and selectivity, making the technique well suited for analysis of samples with high complexity and dynamic range. One of the initial aims of this study was to evaluate the capability to use the developed scFv antibodies for enrichment of the target proteins from a serum background followed by detection and quantification with the use of LC-SRM MS. Combining antibody enrichment with mass spectrometric readout has previously been demonstrated to enable detection of target proteins in complex sample formats such as serum or plasma [8] [9] [10] . More specifically and highly relevant to this study, it has been shown that recombinant scFv antibodies can be used in combination with LC-SRM MS for detection of proteins in a human serum background 11 . Following antibody enrichment in this developed set-up, soluble target proteins M1 and H were detectable in samples down to 4 ng/ml in PBS (Figure 4a & 4b) and for the M1 setup soluble protein were detectable at a concentration of 500 ng/ml in 10% human serum (Figure 5a ).
Targeted antibody enrichment, diminishes the amounts of high abundant proteins to facilitate the detection and quantification of the target proteins. As an example, albumin, the most abundant serum protein, constitute about 60% of the total protein content of serum 45 . Assuming a total protein concentration of serum of 60 mg/ml 45 , the albumin concentration would be more than 5000 times the concentration of M1 protein in our corresponding serum sample and thereby near challenging the dynamic range of the mass spectrometer. We demonstrate the detection of 20 fmol per injection of M1 protein in 10% human serum sample initially containing 500 ng/ml of protein M1 with a theoretical maximum of 417 fmol per injection. This indicates sample loss probably due to the interaction between the M1 protein and different serum proteins as well as an incomplete trypsin digestion. To increase the sensitivity and efficiency of the developed platform the conditions for the different workflow steps, such as capture and wash, could be further evaluated and optimized. Altered pH, buffer choice or detergent concentration as well as incubation timecould potentially improve the binding between the antibodies and the target proteins to increase the efficiency of the platform. An evaluation of the trypsination process could also possible help to diminish the eventual sample loss in the digestion step.
Increased digestion time or extra addition of trypsin could possibly improve the digestion and thereby also the sensitivity of the assay. Yet, protein M1 is still captured and this allows us to detect M1 protein in the samples without the interference from background proteins such as albumin. Both protein H and M1 have the ability of binding albumin while M1 in addition also binds the serum protein fibrinogen 28 . However, the albumin content was measured after enrichment and no albumin was detectable. This highly supports the ability of the developed M1-specific scFv antibodies to make the M1 protein available for detection.
In conclusions, we have generated scFv antibodies with the use of phage display that The data will be open to the public when the paper is accepted to be published.
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